Coherus Bounces Back with Approval of Udenyca Onbody Post-Chemo Drug-Device

Coming back from a complete response letter (CRL) for its Udenyca Onbody drug device combo, Coherus BioSciences has received FDA approval of the product to decrease the incidence of febrile neutropenia after chemotherapy.
Source: Drug Industry Daily